Clin2
NCT06455917Possibly a fitRecruiting

Personalized immune cell therapy for advanced lung cancer

Non-Small Cell Lung CancerLung Cancer (NSCLC)

Part of Cancer, Lungs & breathing clinical trials.

This trial tests a personalized treatment using your own immune cells (called TILs) to fight advanced non-small cell lung cancer that has progressed after standard therapy. You would have surgery to collect a tumor sample, then receive your expanded immune cells back as an infusion.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
30 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have advanced non-small cell lung cancer that has gotten worse after at least one standard treatment
  • You are 18 years or older and willing to have surgery to remove a piece of your tumor
  • You are in generally good health (able to do daily activities without major assistance)
  • Your cancer has not spread to the brain, or if it has, it has been treated and stable for at least a month
  • You do not have another active cancer, serious infections, or autoimmune diseases requiring treatment

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06473961Recruiting· Phase 1
GC101 cell therapy for advanced non-small cell lung cancer

This trial tests an experimental cell therapy (GC101) for people with advanced non-small cell lung cancer. It uses your own tumor-fighting immune cells, called TILs, grown in a lab and given back to you. The goal is to see if it can shrink tumors or slow the disease.

Shanghai
NCT05681780Recruiting· Phase 1
CD40L-treated immune cells for advanced lung cancer with certain gene changes

This Phase 1 study tests a lab-made immune cell treatment (TIL) boosted with CD40L, plus nivolumab, for stage IV or returning non-small cell lung cancer with specific gene changes (EGFR, ALK, ROS1, or HER2). It aims to help your immune system attack the cancer after it has grown despite standard treatments.

Tampa, Florida
NCT07498439Not yet recruiting· Early Phase 1
Immune cell therapy for multiple early-stage lung cancers

This trial tests a new immune therapy using your own white blood cells (tumor-infiltrating lymphocytes) to treat non-small-cell lung cancer that has come back or grown. If you have multiple lung spots or your cancer has progressed after surgery or targeted therapy, this study may offer a treatment option.

NCT03356808Not yet recruiting· Phase 1/Phase 2
Immune cell therapy for advanced lung cancer

This trial tests a personalized immune cell therapy for advanced or relapsed lung cancer. Doctors take your blood, create special T cells that target unique proteins on your cancer, and give them back to you to try to fight the tumor.

Shenzhen, Guangdong
NCT06922266Not yet recruiting
Personalized immune cell therapy for solid tumors

This trial tests a new treatment that uses your own immune cells to fight non-small cell lung cancer. It aims to create a personalized therapy based on your tumor and blood samples.

NCT04842812Recruiting· Phase 1
Personalized immune cell therapy for advanced solid tumors

This Phase 1 study tests engineered immune cells (TILs/CAR-TILs) made from your tumor to treat advanced solid cancers that have not responded to standard treatments. It may help your immune system better recognize and attack the cancer, but it is mainly focused on safety and early results.

Guangzhou

Hear when a new Non Small Cell Lung Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.